PT-141 (Bremelanotide): What's New for Sexual Health Peptides in 2026

PT-141, also known as bremelanotide, is one of the few sexual-health peptides with a real FDA approval to its name. It is approved as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, an indication that has existed since 2019. Outside that label, it shows up most often in off-label prescribing — both for women whose clinical picture sits outside the approved population and for men, where there is no approved indication at all.

The 2026 update is mostly clarifying. The science has not radically changed. What has changed is the regulatory and clinical landscape around how PT-141 is prescribed, what compounded preparations look like, and how a responsible telehealth provider distinguishes legitimate off-label use from the bulk of internet-marketed peptide channels.

What PT-141 actually is

Bremelanotide is a cyclic seven-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is a non-selective melanocortin receptor agonist with primary activity at MC4R, the melanocortin receptor most densely expressed in the central nervous system.¹ MC4R activation in hypothalamic and limbic regions modulates pathways involved in sexual desire and arousal — the dopaminergic and oxytocinergic systems that, downstream, produce the subjective experience of desire and the physiologic preparation for sexual activity.

This is a fundamentally different mechanism from the PDE5 inhibitors (sildenafil, tadalafil, vardenafil), which dominate prescribing for erectile dysfunction. PDE5 inhibitors work peripherally — they block the breakdown of cyclic GMP in vascular smooth muscle, supporting the vasodilation that produces an erection in response to existing arousal. PDE5 inhibitors do not produce desire or arousal; they support the physical response when desire and arousal are already present.

PT-141 works upstream of that. It targets the central pathways that produce the desire and arousal in the first place. For patients whose primary issue is desire (low libido), or for patients whose physical response is intact but central activation is not, this is a meaningfully different mechanism.

The approved indication, and what it does and does not mean

In June 2019, the FDA approved bremelanotide as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.² The two phase 3 trials (RECONNECT) supporting approval enrolled women with HSDD as defined by DSM criteria and demonstrated improvements in sexual desire and decreases in distress related to low desire on validated patient-reported instruments.

The label is narrow on purpose. "Acquired" means the patient previously had typical desire and lost it, not lifelong low desire. "Generalized" means the loss is not situational — not a problem only with one partner, only in one context. "Premenopausal" means the safety and efficacy data behind the approval is in pre-menopause; postmenopausal patients are not in the approved population. And the approval is in women specifically; there is no approved male indication.

The approved dose is 1.75 mg subcutaneously, on demand, at least 45 minutes before anticipated sexual activity, with the explicit limits of one dose per 24 hours and no more than eight doses per month. The on-demand structure matters — Vyleesi is not a daily medication.

Off-label prescribing in men

Bremelanotide is sometimes prescribed off-label to male patients. The clinical justification is mechanistic: the same MC4R-mediated central pathways exist in men, and there is small-trial data, predating the Vyleesi approval, showing PT-141 produces erectile and arousal responses in men as well as women.³ The historical development program for PT-141 actually included male erectile dysfunction populations before being narrowed to female HSDD.

Off-label use is a legal, common practice in US medicine — roughly one in five US prescriptions is written off-label — and is not in itself a flag of inappropriate prescribing. The questions for a responsible clinician are:

• Is the patient a candidate? Not every man with a sexual-health complaint is a PT-141 candidate. Patients whose primary issue is vascular (typical organic ED) are usually better served by PDE5 inhibitors first, with PT-141 reserved for cases where PDE5 inhibitors are contraindicated, inadequate, or where the issue is more clearly central than peripheral.
• Are contraindications screened? The cardiovascular contraindications below apply equally to men.
• Is dosing conservative? Off-label male dosing is typically built around the approved Vyleesi dose, sometimes lower, with conservative titration and the same on-demand structure.

PT-141 is not a first-line ED drug for the typical patient. A telehealth provider that lists it that way is signaling something other than clinical caution.

Mechanism vs. PDE5 inhibitors: when each fits

The cleanest way to think about the two mechanisms is by what the patient's actual complaint is:

• Desire is intact, physical response is the problem. PDE5 inhibitors. The vascular response is the bottleneck; supporting it is what the medication does.
• Physical response is intact, desire and arousal are the problem. PT-141 (off-label in men). The central pathway is the bottleneck.
• Both are problems. Often a layered approach. Some clinicians will trial PT-141 alone first when desire is the clearer issue; others will pair it with a PDE5 inhibitor with appropriate cardiovascular monitoring.
• Neither is the primary problem; the issue is hormonal, psychological, or relational. Neither class is the right answer. A clinician should be assessing testosterone, mental-health context, and partner-dynamics factors before reaching for a medication.

The 2026 update on this question is mostly that the patient pathway has not changed. PT-141 fills a specific niche; it is not a general-purpose sexual-health drug.

Side effect profile

The reported side effect profile for bremelanotide is well characterized from the RECONNECT trials and post-marketing data:

• Nausea. The single most-reported side effect, occurring in roughly 40% of trial patients on at least one dose. Most cases were mild-to-moderate and concentrated in the first one-to-three doses. Anti-emetic pre-treatment is sometimes used in patients who would otherwise discontinue. Nausea is the leading reason for discontinuation.
• Flushing. Common, transient, generally mild.
• Headache. Common, generally mild-to-moderate.
• Transient blood pressure rise. A small but consistent increase in systolic blood pressure (approximately 6 mmHg) and a corresponding small decrease in heart rate are observed in the hours following dosing. This is the cardiovascular signal that drives the contraindication list.
• Focal hyperpigmentation. Darkening of skin patches, particularly on the face, gums, or breasts, has been reported with frequent dosing. This is more common in patients with darker skin types and is one reason the label limits monthly dose count. In most reported cases the pigmentation resolves with discontinuation, but the process can be slow.
• Injection-site reactions. As with any subcutaneous peptide, mild local reactions are common.

Less common but reported: gastrointestinal symptoms beyond nausea, dizziness, and rare reports of focal pigmentation that persists after discontinuation. The cardiovascular signal — not nausea — is the safety variable that drives prescribing decisions.

Contraindications

The hard exclusion list for PT-141, on-label or off-label, includes:

• Uncontrolled hypertension. The transient blood-pressure rise associated with melanocortin agonism is not safe in patients whose baseline blood pressure is already poorly controlled.
• Known cardiovascular disease. Patients with a history of myocardial infarction, stroke, unstable angina, or significant arrhythmia are excluded. The cardiovascular data set behind the approval did not include these populations, and the mechanism is unfavorable for them.
• Pregnancy. Bremelanotide has not been studied in pregnancy and is contraindicated.
• History of melanoma or strong family history. Melanocortin agonism's effect on melanocytes is the mechanism behind the hyperpigmentation findings. Patients with melanoma history or strong family history should discuss the dermatologic risk picture before any prescribing.

Several conditions trigger heightened scrutiny without absolute exclusion: well-controlled hypertension on stable therapy, diabetes with good control, prior history of focal hyperpigmentation concerns. The clinician will weigh these case by case.

How telehealth prescribing of PT-141 should look

A telehealth provider prescribing PT-141 — either Vyleesi on-label or off-label in men — should be doing the following:

1. Screening for cardiovascular contraindications at intake. Blood pressure, cardiac history, current cardiovascular medications. If the patient is not a candidate, that is the answer; there is no dose adjustment that makes them safer.
2. Confirming the indication. For women, that the clinical picture matches HSDD. For off-label male use, that the patient's complaint is actually a candidate for central pharmacology, not vascular.
3. Prescribing within the approved dose structure. 1.75 mg subcutaneously, on-demand, with the monthly dose limit observed. Off-label male protocols sit close to this structure.
4. Following up on tolerability. Nausea is the most common reason for discontinuation; clinicians who anticipate it can keep more patients on therapy. Cardiovascular signal monitoring continues across the prescribing relationship.
5. Documenting and disclosing off-label status when applicable. Off-label prescribing is legitimate; obscuring it is not.

A telehealth provider who is selling PT-141 as a general-purpose sexual-health drug, dosed daily, with no screening, is not doing telemedicine. That is a different business.

Where TelePeptide stands

PT-141 prescribing through TelePeptide is structured around the approved Vyleesi dose for women with HSDD, and around carefully-screened off-label use for men where the clinical picture supports it. Cardiovascular contraindication screening is part of intake. Patients with uncontrolled hypertension or known cardiovascular disease are not candidates. Compounded preparations are made by licensed 503A pharmacies in response to individual prescriptions; compounded medications are not FDA-approved.

PT-141 is not a first-line agent for typical erectile dysfunction. Patients whose presentation is more consistent with vascular ED are routed to PDE5-inhibitor therapy first. PT-141 is one tool among several, prescribed when the clinical picture supports it.

These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity.

Footnotes

1. Pfaus J, Giuliano F, Gelez H. (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine 4 Suppl 4: 269–279. ↩

2. Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5): 899–908. ↩

3. Diamond LE, Earle DC, Rosen RC, et al. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research 16(1): 51–59. ↩